MedTrace Logo

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

NCT04742075 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2026-02-27

No results posted yet for this study

Summary

This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.

Conditions

Interventions

DRUG

Olaparib + durvalumab + UV1

The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.

Sponsors & Collaborators

  • North Eastern German Society of Gynaecological Oncology

    collaborator OTHER

  • Belgian Gynaecological Oncology Group

    collaborator OTHER

  • Hellenic Cooperative Oncology Group (HeCOG)

    collaborator UNKNOWN

  • Arbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO-Austria)

    collaborator UNKNOWN

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Dutch Gynaecological Oncology Group

    collaborator OTHER

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2026-05-01
Completion
2030-12-31

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04742075 on ClinicalTrials.gov